Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to ...

The elephant vaccine closely resembles other mRNA vaccines made for humans. mRNA packed in lipid nanoparticles carries ...

Researchers from Tel Aviv University and the Israel Institute for Biological Research in Ness Ziona have used the platform ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

In this episode presented by Eclipsebio, BioSpace's head of insights Lori Ellis discusses mRNA and srRNA with Andy Geall of ...

The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety of mRNA technology, despite an extensive history of testing.

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

In an interview with The News & Observer, Dr. Barton Haynes talks future of HIV vaccine development after HHS canceled the ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...